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Available online 28 February 2014Abstract Because hyperbaric oxygen treatment mobilizes bone marrow derived-stem/progenitor cells by a free radical
mediated mechanism, we hypothesized that there may be differences in mobilization efficiency based on exposure to different
oxygen partial pressures. Blood from twenty consecutive patients was obtained before and after the 1st, 10th and 20th treatment
at two clinical centers using protocols involving exposures to oxygen at either 2.0 or 2.5 atmospheres absolute (ATA). Post-
treatment values of CD34+, CD45-dim leukocytes were always 2-fold greater than the pre-treatment values for both protocols.
Values for those treated at 2.5 ATAwere significantly greater than those treated at 2.0 ATA by factors of 1.9 to 3-fold after the 10th
and before and after the 20th treatments. Intracellular content of hypoxia inducible factors −1, −2, and −3, thioredoxin-1 and
poly-ADP-ribose polymerase assessed in permeabilized CD34+ cells with fluorophore-conjugated antibodies were twice as high in
all post- versus pre-treatment samples with no significant differences between 2.0 and 2.5 ATA protocols. We conclude that
putative progenitor cell mobilization is higher with 2.5 versus 2.0 ATA treatments, and all newly mobilized cells exhibit higher
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entiation can be mobilized from bone marrow and adipose
tissue, enter the blood stream and migrate to peripheral
sites where they may facilitate recovery from injuries (To
et al., 1997; Gil-Ortega et al., 2013; Asahara et al., 1997).
SPCs mobilization occurs after wounding, physical exertion
and in response to a variety of chemical agents (Fiorina
et al., 2010; Fukaya et al., 2013; Albanese et al., 2009;r CC BY-NC-ND license.
Table 1 Patient characteristics. Details for the Penn and Syracuse treatment centers show age/gender, cancer location, radiation
dose (cGy), other health issues, tobacco and ethanol use. Penn-based patients were 62.1 ± 2.4 (mean ± SE) years old, 5 were female;
and Syracuse-based patients were 62.0 ± 2.5 years old (NS), 5 were female. Radiation dosage was known in 14 Penn-based patients
(6409 ± 133 cGy) and 12 Syracuse-based patients (6635 ± 345, NS). Abbreviations used are as follows: ND, not determined (not
available from chart or the referring physicians); Brachy, brachytherapy; HTN, hypertension; HIV, human immunodeficiency virus
infection; COPD, chronic obstructive pulmonary disease; DM-2, type 2 diabetes mellitus; Ca, cancer; DVT, deep venous thrombosis of a
leg; CAD, coronary artery disease; CVA, cerebrovascular accident; GERD, gastro-esophageal reflux disease; Cholesterol, hypercholes-
terolemia; Esoph, esophageal; Afib, atrial fibrillation; Larengect., laryngectomy; aortic valve, history of aortic valve replacement, HCTZ,
hydrochlorothiazide; and MVI, multivitamin pill.
Age/
gender
Cancer Radiat. Other Medications Tobacco Ethanol
Penn#
1 43 M Tongue 6000 HTN, HIV,
COPD.
Epilepsy,
Asthma
Fosamprenavir, ritonavir,
trimethoprim-sulfamethoxazole
None None
2 67 M Tongue 6600 HTN, DM-2,
Adrenal CA
Amlodipine, terazosin, senna, MVI None Occasional
3 68 M Prostate Brachy,
ND
Depression Morphine, oxycodone, docusate
sodium, omeprazole, citalipram,
cyclobenzaprine HCl, gabapentin
Quit N 6 weeks None
4 58 F Sinus 5400 HTN, DVT,
Cataracts,
Glaucoma
Amlodipine, warfarin, alendronate,
latanoprost gtts, ciprodex gtts
None None
5 39 F Cervix ND Depression Paclitaxel, methadone, gabapentin,
bupropion HCl fluoxetine, pentosan
polysulfate, alprazolam, clonazepam
None Occasional
6 55 M Neck 6530 HTN, CAD,
CVA,
Cholesterol,
Ibuprofen, ranitidine, MVI None None
7 63 M Larynx ND COPD,
Hypothyroid
Gabapentin, levothyroxine Quit N 3 years Occasional
8 68 M Tongue ND Lymphoma,
Hypothyroid
Ramapril, levothyroxine None Occasional
9 57 M Tonsil 6300 None Pregabalin, oxycodone, lansoprazole,
MVI, glycopyrrolate
Quit N 3 years Occasional
10 67 M Tongue 7000 GERD Esomeprazole None None
11 48 M Tonsil 6300 Asthma Albuterol, gabapentin, glycopyrrolate,
oxycodone
Quit N 5 years None
12 65 F Tongue 5580 Hypothyroid,
Cataracts
Levothyroxine None Occasional
13 76 M Prostate ND HTN,
Cholesterol
Metoprolol, amlodipine, prevastatin Quit N 25 years Occasional
14 79 M Tongue 6820 HTN, DM-2,
COPD
Metoprolol, losartan, HCTZ, irbesartan,
chlorpheniramine- hydrocodone syrup
Quit N 15 years Occasional
15 68 F Tongue 7000 HTN, GERD,
Cholesterol,
CAD
nebivolol, clopidogrel, rosuvastatin,
metoclopramide
Quit N 3 years Occasional
16 56 M Tongue ND Cholesterol,
CAD
Pentoxifylline, rosuvastatin, oxycodone None Occasional
17 78 M Prostate Brachy,
ND
HTN, Crohn's Atenolol None None
18 56 M Neck 6600 HTN,
Migraine,
Cholesterol,
Gout
Ezetimibe, pitavastatin, rizatriptan,
allopurinal
Quit N15 years Occasional
19 70 M Tongue 7000 HTN,
Hypothyroid,
Lisinopril, celecoxib, tramadol, trazodone,
gabapentin, levothyroxine, MVI
None Occasional
20 60 F Tonsil 6300 None Pentoxyfylline, oxycodone None Occasional
(continued on next page)
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Table 1 (continued)
Age/
gender
Cancer Radiat. Other Medications Tobacco Ethanol
Syracuse#
1 50 M Tonsil 6996 ITP Prednisone, oxycodone, xanax,
fentanyl, sertraline
Chew None
2 73 F Tonsil 7000 COPD,
Esoph Ca
Albuterol, fluticasone,
esomeprazole, mometasone
Quit N 5 years None
3 53 M Mouth 7300 HTN Morphine, oxycodone, colace,
omeprazole, citalipram,
cyclobenzaprine, gabapentin
Quit N 6 weeks None
4 72 M Prostate 6600 Cholesterol Simvastatin Quit N 5 years None
5 55 M Mouth ND AFib, Aortic
valve
Coumadin, carvedilol, amlodipine,
fluticasone, albuterol, acetaminophen-
hydrocodone
None None
6 61 M Mouth ND HTN, Esoph
strictures
Bisacodyl, lisinopril, omeprazole,
ranitidine, sulfamethoxazole,
trazadone
Quit N 8 weeks Occas.
7 60 M Mouth 6600 None Ibuprofen, ranitidine, MVI None None
8 53 M Palate 7000 Sinusitis Pregabalin Quit N 3 years Occas.
9 57 M Larynx ND Laryngect. Gabapentin, cyclobenzaprine,
oxycodone, nortriptyline, HCTZ
Quit N 3 years None
10 68 M Tongue 6400 Lung CA,
COPD
Alendronate, travatan opthalmic sol,
albuterol inh, levothyroxine,
fluticasone inh, ferrous sulfate
Quit N 5 years None
11 76 F Breast ND Aortic valve Bumetanide, atorvastatin omeprazole,
ASA, levothyroxine, KCl, fluticasone,
naproxen, acetaminophen-hydrocodone,
pseudoephedrine, Vitamin D, MVI
None None
12 79 M Prostate ND HTN,
Colon CA
Coumadin, amlodipine, atorvastatin,
HCTZ, bicalutamide
Quit N 5 years None
13 57 F Larynx 6996 HTN Lisinopril, methimazole, carvedilol 1 PPD None
14 51 M Neck ND HTN,
Cholesterol,
Hypothyroid
Levothyroxine, bisoprolol, pantoprazole,
pravachol, MVI
None Occas.
15 46 M Mouth ND None Acetaminophen 1 PPD None
16 69 M Prostate 7740 HTN,
Cholesterol,
Asthma
Albuterol inh, fluticasone inh,
tiotropium inh, amlodipine,
rosuvastatin, acetaminophen,
fluticasone
None None
17 82 F Mouth 3000 HTN, CAD,
Dialysis
Levothyroxine, isosorbide,
vitamin b complex, donepezil,
metoprolol, oxycodone, mesalamine,
citalopram, nortriptyline, omeprazole,
diphenoxylate, folate, MVI
None None
18 69 F Tongue ND HTN.
Cholesterol,
Asthma
Albuterol inh, amlodipine, atorvastatin None None
19 46 M Palate 6996 Epilepsy Lamictal, omeprazole, triamcinolone None None
20 62M Tongue 6996 HTN HCTZ Quit N 5 years None
640 M. Heyboer et al.Asahara et al., 1999; Rehman et al., 2004; Reyes et al.,
2002; Takahashi et al., 1999). Exposure to hyperbaric oxygen
(HBO2) appears to be a reliable way to mobilize SPCs in
humans and also has been shown in rodents and horses
(Thom et al., 2006, 2011; Ma et al., 2011; Milovanova et al.,
2009; Dhar et al., 2012). Animal studies indicate that one
mechanism is based on activation of nitric oxide synthase
type 3 (NOS-3) in bone marrow stromal cells with subsequent
liberation of stem cell factor (Thom et al., 2006; Goldsteinet al., 2006). Separate from mobilization, HBO2 improves
engraftment and differentiation of several progenitor cell
types in organs such as the spleen, bone marrow, brain,
peripheral nerve, pancreas, cartilage and heart (Aljitawi
et al., 2014; Lee et al., 2013; Cherng et al., 2012; Khan
et al., 2012; Zhang et al., 2010, 2011; Pan et al., 2009). One
area of interest with circulating SPCs is the identification of
the sub-set having propensity to form vascular endothelium,
so-called endothelial progenitor cells (EPCs) (Hirschi et al.,
641Stem cell mobilization by hyperbaric oxygen2008). Quantification of mobilized EPCs is based on flow
cytometric detection of cell surface proteins and phenotypic
manifestations of laboratory-grown clones (Hirschi et al., 2008;
Mund et al., 2012). Cells mobilized by HBO2 exhibit many of
these surface markers and when cultured, some clones show
lectin binding consistent with an endothelial phenotype (Thom
et al., 2006, 2011). Animal studies have documented that
HBO2-mobilized SPCs form blood vessels in vivo and hasten
wound healing (Milovanova et al., 2009; Goldstein et al., 2006;
Gallagher et al., 2007).
HBO2-mobilized SPCs have greater content of hypoxia
inducible factors (HIFs) and thioredoxin-1 (Trx), which in
the murine model confers improved neovascularization (Thom
et al., 2011; Milovanova et al., 2008, 2009). Subsequent to
HBO2 treatments of refractory wounds and diabetic patients,
the number of wound margin SPCs is increased and local HIFs
and Trx appear to be within these localized SPCs (Thom et al.,
2011; Ma et al., 2011). This suggests that SPCs play a role in
supplying factors required for wound healing. Hence, evaluat-
ing intracellular proteins may have greater importance to
assess SPCs function versus ex vivo manipulations. Assess-
ment of intracellular regulatory proteins of cells selected
based on surface markers precludes studying ex vivo cell
growth because of need to permeabilize the cell membranes.
HBO2 treatment involves breathing 100% O2 at 2 to 3
atmospheres absolute (ATA) pressure for 1.5 to 2 h once or
twice daily. HBO2 has been shown to improve refractory
diabetic wounds and delayed radiation injuries in random-
ized trials and use is supported by independent evidence-
based reviews (Bennett et al., 2008; Clarke et al., 2008;
Kranke et al., 2012; Goldman, 2009; Fife et al., 2007; Duzgun
et al., 2008; Londahl et al., 2010). Several studies have failed
to identify clinical efficacy (Annane et al., 2004; Margolis
et al., 2013). Notably, these studies involved exposures to
2.0 ATA or use of face masks with questionable seals thus
reducing the fraction of inspired O2; whereas several prospec-
tive randomized trials documenting therapeutic benefit utilized
pressures of 2.4 or 2.5 ATA in pure O2-filled chambers or using
head-covering hoods (Londahl et al., 2010; Marx et al., 1985).
Whether clinical results may differ because of treatment
protocols is unclear. The goal of this investigation was to
evaluate whether mobilization of cells with surface markers
considered consistent with SPCs (CD34+ and CD45-dim) and
content of intracellular regulatory proteins differed between
two commonly used HBO2 protocols (Pober, 2012).Methods
Patient management protocols
All procedures were approved by the Institutional Review
Boards and patients signed informed consent. A consecutive
series of patients was approached who had been referred for
HBO2 treatment because of complications from radiotherapy
for cancer. On the basis of current standard of care, they
were to receive at least 20 HBO2 therapy sessions. Patient
characteristics are shown in Table 1. Venous blood was
collected prior to and after the 1st, 10th and 20th HBO2
treatments into Cyto-Chex BCT test tubes (Streck, Inc., Omaha,
NE) that contain a proprietary preservative. Samples from thesame day of treatment (pre- and post-HBO2) were analyzed
concurrently within 3 days of collection.
The standard Penn-based practice for delivering O2 involved
placement of a balloon-cushioned face mask that is normally
used for continuous positive airway pressure respiratory
therapy. Treatments were conducted at 2.0 ATA for 2 h
daily, 6 days/week. Intermittently the fractional inspired O2
content in the mask was verified to be 100%. Syracuse-based
treatments were conducted in an acrylic chamber pressurized
with pure O2 so that no special mask was required to assure
100% O2 delivery. Treatments were at 2.5 ATA for 90 min daily,
6 days/week.Flow cytometry
CD34+ and CD45-dim cells and relative concentrations
of intracellular proteins were evaluated with a 10-color
FACSCanto (Becton Dickinson, San Jose, CA) using standard
acquisition software following published techniques (Thom
et al., 2011; Milovanova et al., 2008, 2009). Briefly, nucleated
cells were segregated from debris by DRAQ5 DNA staining
and gates were based on true-negative controls according to
fluorescence-minus-one analysis. Anti-actin fluorescence
confirmed uniform cell permeabilization for intracellular
protein analysis. Fluorescence/cell was determined and
used to compare pre- versus post-HBO2 cell populations.Materials
Chemicals were purchased from Sigma-Aldrich (St. Louis,
MO). Antibodies were purchased from the following sources:
From BD Pharmingen, San Jose, CA. R-phycoerythrin (PE)-
conjugated mouse anti-human CD34 (Clone 581, a class III
CD34 epitope; catalog number 555822), fluorescein isothio-
cyanate (FITC)-conjugated mouse anti-human CD45, catalog
number 5558710 and allophycocyanin (APC)-conjugatedmouse
anti-human poly-ADP ribose polymerase (PARP) catalog num-
ber 558710; from R & D Systems, Minneapolis, MN, APC-
conjugated anti-human hypoxia inducible factor (HIF)-1,
catalog number IC1935P; from Novus Biologicals, Littleton,
CO , PE-conjugated anti-human HIF-2 (catalog number NB100-
122), FITC-conjugated anti-human HIF-3 (catalog number
NB100-2529) and anti-human Trx catalog number EPR 6111
with secondary from Invitrogen, Grand Island, NY catalog
number T-2769.Statistical analysis
Statistical analysis of stem cell numbers and quantitative
changes in wound proteinmarkers were carried out by repeated
measures analysis of variance followed by the Tukey test
for multiple comparisons (SigmaStat, Jandel Scientific, San
Rafael, CA). Statistical significance was taken as p b 0.05.
Data sets were found to be normally distributed so results
are displayed as mean ± SE, n = 20 for all groups. Pre- and
post-treatment comparisons were made within each type (2.0
ATA and 2.5 ATA) and between the 2.0 and 2.5 ATA treatments
for each number (1st, 10th and 20th) by two-tailed t-test.
Figure 1 Leukocyte mobilization by HBO2. The number of circulating CD34+, CD45-dim cells in blood before and after the 1st, 10th
and 20th treatment of 20 patients exposed to at either 2.0 or 2.5 ATA. Data were normalized to blood volume (gray boxes quantified
on the left ordinate axis) or to total circulating leukocyte count (black boxes quantified on the right ordinate axis) and are mean ± SE,
* indicates significant difference between 2.0 and 2.5 ATA groups (ANOVA). All post-HBO2 values are significantly different from
pre-HBO2 values at each treatment time in both groups (t-test).
642 M. Heyboer et al.Results
Circulating cells
Circulating CD34+ and CD45-dim leukocytes increased in
blood from 20 consecutive patients undergoing HBO2 therapy
following a protocol of either 2.0 ATA or 2.5 ATA (Fig. 1).
There were no significant differences in age, gender or
radiation dose between groups (Table 1). Following the 10th
as well as before and after the 20th treatment cell counts
were significantly higher with the 2.5 ATA versus the 2.0 ATA
protocol. Findings were essentially the same whether normal-
ized to volume of blood (left axis of Fig. 1) or to total circulating
leukocyte count (right axis) because total leukocyte counts forTable 2 Intracellular protein content (fold-elevation post- versu
Protein Treatment #
HIF-1 1
10
20
HIF-2 1
10
20
HIF-3 1
10
20
Trx 1
10
20
PARP 1
10
20
Data showmean ± SE fold-differences in fluorescence of post-versus p
antibodies to proteins shown in column 1. All post-HBO2 values are s
differences between the 2.0 and 2.5 ATA protocols.patients did not differ significantly over the course of the HBO2
treatments (data not shown).Intracellular protein concentrations
Significant elevations of intracellular regulatory proteins
were found in permeabilized CD34+ cells after the 1st, 10th
and 20th treatments with either protocol (Table 2). Because
of variations in fluorescence intensity due to different lots
of antibody and also flow cytometer laser intensities, only
differences in cell fluorescence intensity for pre- and post-
HBO2 samples analyzed on the same day were compared and
not intensity across a 20 treatment course.s prior to HBO2).
2.0 ATA Protocol 2.5 ATA Protocol
2.35 ± 0.24 3.29 ± 0.55
2.65 ± 0.21 2.67 ± 0.22
2.54 ± 0.38 2.77 ± 0.26
2.33 ± 0.24 2.68 ± 0.30
2.48 ± 0.15 2.54 ± 0.20
2.54 ± 0.23 2.60 ± 0.21
2.27 ± 0.22 2.67 ± 0.31
2.38 ± 0.24 2.29 ± 0.15
2.43 ± 0.26 2.27 ± 0.15
2.34 ± 0.24 2.51 ± 0.26
2.36 ± 0.22 2.28 ± 0.13
2.44 ± 0.24 2.50 ± 0.29
2.36 ± 0.22 2.64 ± 0.26
2.39 ± 0.22 2.42 ± 0.19
2.57 ± 0.27 2.47 ± 0.22
re-HBO2 permeabilized CD34+ cells using fluorophore-conjugated
ignificantly different from pre-HBO2 and there are no significant
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The results demonstrate that O2 partial pressure influences
SPCs mobilization with repetitive treatments. Whether this
is due to augmented NOS-3 activation requires additional
study. SPCs mobilization in response to a variety of drugs is
compromised by older age, prior radiotherapy and use of
several types of chemotherapy (e.g. platinum compounds,
alkylating agents, purine analog and lenalidomide) (Jantunen
and Kvalheim, 2010). None of these agents were being
administered to patients during our study. We have reported
previously that SPCsmobilization in response to a single 2.0 ATA
O2 exposure is the same between normal adults and those
exposed to radiotherapy (Thom et al., 2006). Obviously, all
patients in this study received radiotherapy but there was
no significant difference in radiation dosage or patient age
between the 2.0 and 2.5 ATA treatment groups (Table 1).
There were no notable deviations in the pattern of SPCs
mobilization among the patients despite taking a variety of
medications listed in Table 1. Some of these medications
are known to have positive effects on SPCs mobilization
(e.g. short term statin use, paclitaxel, certain β-blockers
such as nebivolol and carvedilol); while others have a negative
impact on mobilization (e.g. bisphosphonates, long-term use
of statins and trimethoprim/sulfamethoxazole) (Hristov et al.,
2007; Sorrentino et al., 2011; Besler et al., 2008; Wu et al.,
2010; Fuchs et al., 2000; Xu et al., 2013; Fernandez et al.,
2008). None of the medications listed in Table 1 had been
started in the time frame while patients were receiving HBO2
and all had been prescribed for over 2 months prior to patient
enrollment. One patient in the 2.0 ATA group hadHIV and one in
the 2.5 ATA group had renal failure andwas undergoing dialysis.
HIV does not impede the efficacy of chemotherapeutic agent-
mediated SPCs mobilization and renal failure may modify
mobilization by some drugs but does not completely abrogate
responses (Badros et al., 2001; Hill et al., 2012; Re et al., 2013;
Gabarre et al., 2000). Whether these disorders influence HBO2-
mediated mobilization will require additional study. Clearly,
there are differences in mobilization mechanisms between
chemotherapeutic agents and HBO2. Contrary to many of the
stem cell mobilization drugs HBO2 does not activate platelets
or elevate leukocyte counts which can be thrombogenic (Ma
et al., 2011; Powell et al., 2005; Thom, 2006, 2009).
Intracellular regulatory protein contents were elevated in
all post-HBO2 samples with no significant differences between
protocols. Elevations are likely a characteristic of the bone
marrow SPCs population primed for mobilization and a higher
percentage is released with higher O2 dose. Lower protein
levels in pre-HBO2 samples at the 10th and 20th treatments
may reflect preferential perivascular sequestration of newly
mobilized cells and/or protein degradation in cells remaining
in the circulation for many hours. The difference in protein
contents of newly mobilized SPCs has not been appreciated in
mobilization studies involving chemotherapeutic agents. This is
probably because responses to chemical agents proceed over a
much longer time course.
A weakness of this investigation is that perhaps alterna-
tive or additional surface markers should be used to better
characterize the mobilized cells. With regard to neovascu-
larization potential, this is difficult to determine given
the ongoing debate over EPCs characterization (Pober,
2012). Elevated intracellular proteins of HBO2-mobilizedcells suggest they may have improved propensity for growth/
differentiation based on animal studies (Milovanova et al.,
2008, 2009). HIF-3 and PARP were probed because they provide
evidence that cells were not merely circulating endothelial
cells or cells undergoing apoptosis. PARP levels would be
expected to be quite low in apoptotic cells (Gajdusek et al.,
2001). EPCs can be distinguished from mature CECs by
determining ‘clonogenic’ proliferative capacity, but not by
flow cytometric evaluation of surface markers (Pober, 2012).
Our approach for assessing intracellular markers after mem-
brane permeabilization precludes ex vivo growth analysis,
which is why we probed for HIF-3. In animals we have found
HBO2-mobilized SPCs that form newblood vessels and hence not
CECs are well endowed with HIF-3, whereas HIF-3 normally is
highly tissue restricted (to thymus, lung and a lesser extent in
brain, heart and kidney) (Milovanova et al., 2009; Gu et al.,
1998). Therefore, we conclude that the cells mobilized by
hyperoxia are SPCs and that treatment pressure influences
mobilization efficiency. Functional consequences of this re-
sponse require further study.References
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